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Abstract
Background: The acquisition of proliferative and invasive phenotypes is considered a hallmark of neoplastic
transformation; however, the underlying mechanisms are less well known. Lipid phosphate phosphatase-3 (LPP3)
not only catalyzes the dephosphorylation of the bioactive lipid sphingosine-1-phosphate (S1P) to generate
sphingosine but also may regulate embryonic development and angiogenesis via the Wnt pathway. The goal of
this study was to determine the role of LPP3 in tumor cells.
Results: We observed increased expression of LPP3 in glioblastoma primary tumors and in U87 and U118
glioblastoma cell lines. We demonstrate that LPP3-knockdown inhibited both U87 and U118 glioblastoma cell
proliferation in culture and tumor growth in xenograft assays. Biochemical experiments provided evidence that
LPP3-knockdown reduced b-catenin, CYCLIN-D1, and CD133 expression, with a concomitant increase in
phosphorylated b-catenin. In a converse experiment, the forced expression of LPP3 in human colon tumor (SW480)
cells potentiated tumor growth via increased b-catenin stability and CYCLIN-D1 synthesis. In contrast, elevated
expression of LPP3 had no tumorigenic effects on primary cells.
Conclusions: These results demonstrate for the first time an unexpected role of LPP3 in regulating glioblastoma
progression by amplifying b-catenin and CYCLIN-D1 activities.
Background
The lipid phosphate phosphatases (LPPs) have been
shown to dephosphorylate sphingosine 1-phosphate
(S1P) and its structural homologs to produce metabolic
products such as sphingosine, ceramide, and lysopho-
sphatidic acid (LPA) [1-3]. Three major isoforms, LPP1,
LPP2, and LPP3 have been studied in various tissues
and cell lines [3,4], however, the role of LPPs in tumor
progression is not well understood [1-4]. Although LPPs
are localized to the endoplasmic reticulum (ER), cyto-
plasm and plasma membrane [5,6], LPPs also associate
with membrane microdomain rafts and caveolae [5-7].
Ovarian carcinoma cells secrete a high concentration of
S1P and LPA [8,9]. Accordingly, overexpressing sphin-
gosine kinase 1 (Sphk1), one of the main enzymes that
catalyzes the formation of S1P, results in increased
t u m o r i g e n i ca c t i v i t yi nt h eMin mouse model of intest-
inal tumor progression [10].A d d i t i o n a l l y ,e l e v a t e d
expression of LPPs has been postulated to reduce the
level of S1P and its structural homologs, thereby down-
regulating cell signaling. In support of this notion, in
vitro experiments have provided evidence for the ability
of LPPs to down-regulate the activity of extracellular
signal-regulated kinase (Erk)1/2 and induce death of
ovarian carcinoma cells [11,12]. However, LPP3 has
been shown to be highly expressed in sprouting
endothelial cells and can act as a cell associated integrin
ligand [13-15]. Accordingly, we have shown that an anti-
body against the extracellular domain of LPP3 inhibits
cell-cell interactions and angiogenesis in vitro [14-16].
I nas e p a r a t es t u d y ,w eh a v ea l s os h o w nt h a tL P P 3i s
required for tumor adaptation and b-catenin signaling
[17,18]. These observations provided us with the initial
impetus to carry out this study on the role of LPPs in
the acquisition of neoplastic cellular behavior.
In addition to binding to E-cadherin, a key role for b-
catenin has been established in Wnt (wingless) signaling.
The activation of canonical Wnt signaling promotes the
translocation of b- catenin to the nucleus, where it acts
as a co-activator for the transcription factor T-cell
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complex. Increased Wnt/b-catenin signaling has been
linked to cancer cell proliferation, stem cell self-renewal,
and angiogenesis. In this regard, b-catenin signaling is
often shown to up-regulate transcription of the
CYCLIN-D1 protein. CYCLIN-D1 is a key regulator of
cell cycle progression, the increased expression of which
is a fundamental characteristic of tumor cell prolifera-
tion. Although Lpp3 is essential for vasculogenesis,
aspects of embryonic development and Wnt signaling
[19], the function of LPP3 during pathological processes,
including tumor growth, remains unknown. A few
reports have focused on the role of LPPs in angiogenesis
[14,16-19], but none has reported the expression pat-
terns of LPP3 in human primary tumors or tumor cell
lines. Importantly, the association of increased LPP3
expression with cell transformation and tumorigenesis
has not been reported. To test whether LPP3 regulates
tumor cell behavior, we knocked down LPP3 and inves-
tigated glioblastoma cell proliferation and tumor
formation; conversely, we forced expression of LPP3 in
LPP3-deficient human colon carcinoma (SW480) cells
to address the hypothesis that LPP3 potentiates cell pro-
liferation and tumor growth.
Results
Expression of LPP3 Protein in a Subset of Primary Tumors
Expanding upon our previous reports [13,14], we
assessed the expression of LPP3 protein in primary
tumors of various histotypes. The specificity of anti-
LPP3-C-cyto has been addressed in our previous publi-
cations [13-18]. Using this antibody, we noted increased
expression of LPP3 in glioblastoma (GBM), small intes-
tine, and pancreatic tumor samples (Figure 1A). LPP3
expression was low in colon, duodenum, large intestine,
and rectal tumor samples. LPP3 expression in liver
tumors was not detectable, except for a non-specific
high molecular weight species (~125 kDa; Figure 1A). In
keeping with the survey, cell lines of different histotypes
corresponding to high and low/undetectable LPP3 levels
Figure 1 Expression of LPP3 in primary tumors. (A) Western blot was probed with an anti-LPP3-C-cyto antibody. Each lane contained 10 μg
total protein prepared from primary human tumor tissues. LPP3 protein is indicated by two black arrows. (B) Tumor line cell extracts were
analyzed by WB with the indicated antibodies. All blots shown are representative of those obtained from at least three separate experiments
with similar results.
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anti-LPP3-C-cyto antibody primarily detected one
immature 32-33 kDa (indicated by two black arrows)
and one mature 38-40 kDa polypeptide species (Figure
1A). Maturation of LPP3 protein requires N-glycosyla-
tion [14,16]. Since primary tumors are not likely syn-
chronized, these cells could express both mature and
immature forms of LPP3 polypeptides. The human glio-
blastoma cell lines, U87 and U118, expressed LPP3,
whereas SW480 human colon tumor cells did not (Fig-
ure 1B, top panel). Compared to SW480 cells, U87 and
U118 cells expressed appreciably higher levels of b-cate-
nin and CYCLIN-D1 (Figure 1B). Interestingly, SW480
did not express a detectable level of CD133 (a marker of
stem cells), while U87 and U118 cells expressed CD133
(Figure 1B). We also analyzed an array of 63 glioblas-
toma tissue sections that were glial fibrillary acidic pro-
tein (GFAP) positive; of 63 sections analyzed, 11
sections demonstrated anti-LPP3-RGD antibody immu-
noreactivity (Figures 2A and 2B). We expanded the ana-
lysis to a series of well-characterized primary pancreatic
tumors, in which we detected cytosolic expression of
LPP3 in both endocrine and exocrine normal pancreas,
and in 41/63 pancreatic tumors of neuroendocrine ori-
gin with evidence of altered subcellular (nuclear) locali-
zation in 40% of the cases (Figures 2C-F). These data
suggest that LPP3 expression is increased in a subset of
solid tumors and in U87 and U118 glioblastoma tumor
cell lines.
LPP3-Knockdown Reduces Glioblastoma Tumor Cell
Proliferation and Migration
The acquisition of increased proliferative and migratory
phenotypes is a hallmark of neoplastic cells. Given that
b-catenin and CYCLIN-D1 are known regulators of
tumor cell proliferation and migration, we examined the
relationship between LPP3 expression and b-catenin and
CYCLIN-D1 in U87 and U118 glioblastoma cell prolif-
eration and migration. The timeline of this experiment
is shown in Figure 3A. We observed that LPP3 deple-
tion significantly inhibited the proliferation of both U87
and U118 cells, whereas control shRNA had no effect
Figure 2 Immunohistochemistry of primary tumors. (A) A representative serial section of human glioblastoma was stained with hematoxylin
and eosin (H&E), white arrows indicate microvascular proliferation, and (B) black arrows indicate anti-LPP3-RGD positive glioblastoma cells. Scale
bars, 100 μm. (C) Anti-LPP3 staining in normal pancreas show cytosolic expression in both endocrine (Islet of Langerhans-arrow) and exocrine
components. (D, E) In pancreatic endocrine tumors, 65% of the tumors show cytosolic staining. Inset: Nuclear localization of LPP3 is also
detected in 40% of cases. (F) An example of LPP3-negative tumor cells. All experiments are representative of those obtained in at least three
separate experiments, with similar results.
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shown (Figure 3C-F). LPP3 knockdown decreased b-
catenin and CYCLIN-D1 expression in both U87 and
U118 cells, whereas it had no effect on GAPDH levels
(Figure 3G).
To examine the effect of LPP3 knockdown on cell
migration, we carried out a cell migration assay using a
chemotactic Boyden chamber (Figure 4). The timeline of
this experiment is shown in Figure 4A. LPP3
knockdown reduced the migration of both U87 and
U118 cells in the Boyden chamber assays, whereas con-
trol shRNA had no effect (Figure 4B). The efficiency of
LPP3 knockdown was close to 100% in U87 cells and
was 80-90% in the U118 tumor line (Figure 4C). LPP3
knockdown had no effect on LPP2 protein level (Figure
4C), but it increased the level of phosphorylated b-cate-
nin species. Thus, the b-catenin level decreased (Figure
4C), and the level of CYCLIN-D1 was concomitantly
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Figure 3 LPP3 regulates glioblastoma cell proliferation. (A) The time line indicates when glioblastoma cell lines were plated, shRNA
(retrovirus) mediated knockdown was conducted, cells were growth factor and serum starved, fresh medium was added, BrdU (1.0 μg/ml) was
added, and the proliferation assay was performed. (B) Quantification of glioblastoma cell proliferation assay. The data represent the mean ± s.e.
m. n = 5-7 from five to seven independent experiments, ¥ P < 0.05 vs. control untreated; ¶ P < 0.05 vs. control shRNA treated group. (C-F)
Representative images of the BrdU assay. Arrows indicate BrdU positive cells. Scale bar, 150 μm. (G) The efficiency of knockdown of LPP3 was
assessed by western blotting with the indicated antibodies. Figure 3G (top panel, last lane, anti-LPP3), a partial band is likely produced by over
flow from the neighboring well. All experiments are representative of those obtained in at least three separate experiments with similar results.
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LPP3 knockdown reduced cell proliferation and migra-
tion by down-regulating b-catenin and CYCLIN-D1
activities.
LPP3 Knockdown Reduced U87 and U118 Glioblastoma
Tumor Growth
Next, we performed LPP3 knockdown in U87 and U118
cell lines and tested their ability to grow in a xenograft
experiment (Figure 5). First, we assessed the effect of
LPP3 depletion on b-catenin and CYCLIN-D1 levels by
western blot analysis (Figure 5A). LPP3 depletion
decreased total b-catenin, CYCLIN-D1, and CD133 pro-
tein, whereas it had no effect on LPP2 or GAPDH pro-
tein levels (Figure 5A). To examine the effect of LPP3
depletion in U87 and U118 cells, conditioned media
were collected and subjected to ELISA for the presence
of vascular endothelial growth factor (VEGF) and inter-
leukin-8 (IL-8), both of which are known downstream
targets of canonical Wnt signaling. We included tissue
inhibitor of metalloproteinases-2 (TIMP-2) as a control
(Figure 5B). LPP3-depleted U87 and U118 cells pro-
duced significantly decreased concentrations of VEGF
and IL-8, whereas TIMP-2 levels remained unchanged
(Figure 5B). In the xenograft experiment, mice receiving
U87 and U118 that had been treated with control
shRNA showed significant tumor growth after 14 and
28 days (Figure 5C). In contrast, LPP3-depleted U87
and U118 cells showed reduced tumor growth (Figure
5C). Representative images of the xenograft experiment
are shown (Figure 5D) and suggest that LPP3-depletion
in glioblastoma tumors reduces tumor growth by dam-
pening b-catenin and CYCLIN-D1 activity.
Elevated Expression of LPP3 Potentiates SW480 Growth in
Xenograft Assay
To test the ability of LPP3 to regulate tumor growth, we
used LPP3-deficient SW480 colon tumor cells to investi-
gate the relationship between elevated expression of
LPP3 and tumor growth. SW480 harbors two mutant
alleles of the APC gene [20], which results in the stabili-
zation of b-catenin. First, we prepared retroviral
Figure 4 LPP3 regulates glioblastoma cell migration. (A) The time line indicates when glioblastoma cell lines were plated, shRNA (retrovirus)
mediated knockdown was conducted, medium was added, and the migration assay was performed as described in materials and methods. (B)
Quantification of glioblastoma cell migration through the Boyden chamber. The data represent the mean ± s.e.m. n = 5-7, ¥ P < 0.05 vs. control
shRNA treated group. (C) Efficiency of knockdown of LPP3 was assessed by western blotting with the indicated antibodies. All experiments are
representative of those obtained in at least three separate experiments with similar results.
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(Figure 6A) and generated stable clones. Because results
obtained from over-expression experiments can be
ambiguous, only clones that displayed the lowest expres-
sion levels were selected. Clones expressing comparable
levels of hLPP1, hLPP2, hLPP3 and mLpp3 proteins
were selected based on the results of western blot analy-
sis (Figure 6B). b-catenin was not increased in SW480
cells that expressed hLPP1 or hLPP2. In contrast, the
stability of b-catenin and CYCLIN-D1 protein was
increased in SW480 cells that expressed hLPP3 or
mLpp3 (Figure 6B). As athymic nude mice do not
mount an immunogenic response to xenografts, we
investigated the role of elevated LPP3 expression of in
SW480 cells using these mice. We observed minimal
tumor growth after 14 and 28 days in mice that received
LPP3-deficient SW480 cells expressing vector alone or
hLPP1 or hLPP2 (2 × 10
4 tumor cells/site) (Figure 6C).
Figure 5 LPP3 regulates glioblastoma tumor growth. (A) Stable clones of U87 and U118 were selected and efficiency of knockdown was
determined by western blotting with the indicated antibodies. LPP3-knockdown decreased total b-catenin, CYCLIN-D1, and CD133 proteins,
whereas it had no effect on LPP2 or GAPDH. (B) Conditioned media were collected and subjected to ELISA for VEGF, IL-8, and TIMP-2. LPP3-
knockdown in U87 and U118 cells reduced the concentration of VEGF and IL-8, whereas TIMP-2 was unaffected. (C) In the xenograft assay, mice
receiving cells that expressed control shRNA showed increased tumor growth (n = 12, ¥ P < 0.05) after 14 and 28 days. LPP3-knockdown
reduced U87 and U118 tumor growth (n = 12, ¶ P < 0.05). (D) Representative images from the xenograft assay. Dotted circles indicate the
location of tumor implants.
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grew significantly (n = 12, ¶ P < 0.01 vs. hLPP1 group)
within 28 days. Closer examination of hLPP3- and
mLpp3-expressing tumors showed a vascularized tumor
with localized hemorrhaging, indicative of aggressive
tumor growth (Figure 6D). In contrast, hLPP1, hLPP2,
hLPP3 or mLpp3 did not transform NIH-3T3 cells in
culture (data not shown). Together, these data strongly
suggest that LPP3 is not a tumor promoting factor, but
it amplifies b-catenin signaling and CYCLIN-D1 activity
to potentiate SW480 growth.
Both the RGD and the Lipid Phosphatase Domains of
LPP3 are required for SW480 Tumor Growth
To elucidate which domain of LPP3 regulates b-catenin
stability and CYCLIN-D1 expression, thereby potentiat-
ing SW480 tumor growth, we prepared pLNCX2-based
vector alone (construct-a), wild-type (construct-b,
hLPP3), adhesion defective mutant (construct-c, hLPP3-
RAD), phosphatase-inactive mutant (construct-d,
hLPP3-PI), and double mutant (construct-e, hLPP3-RAD
+ PI) constructs (Figure 7A). Stable colonies of SW480
cells were prepared and then selected for equivalent
protein expression by western blotting with anti-HA
antibodies (Figure 7B, top panel). There was no anti-HA
immunoreactive species in the pLNCX2-based vector
alone (construct-a). We also determined total b-catenin
levels, the phosphorylation status of b-catenin, and
CYCLIN-D1 levels prior to performing the tumor
implantation experiment (Figure 7B). We observed
decreased b-catenin phosphorylation in SW480 cells
that expressed hLPP3 (construct-b), whereas there was
no major change in the total level of b-catenin in these
cells (Figure 7B). For the xenograft assay, only those
clones that displayed low expression levels were used.
SW480 cells expressing the indicated constructs were
then injected into nude mice subcutaneously (s.c.), and
tumor volume was examined after 21 days (Figure 7C).
Tumor growth in control mice (construct-a) was mini-
mal (Figure 7C). However, we observed increased tumor
growth in mice that received SW480 cells expressing
hLPP3, but this effect was significantly reduced in mice
Figure 6 Forced expression of LPP3 potentiates SW480 tumor growth in the xenograft assay. (A) pLNCX2-based retroviral constructs
expressing vector alone, hLPP1, hLPP2, hLPP3 or mLpp3 cDNAs. (B) The comparable levels of hLPP1, hLPP2, hLPP3 and mLpp3 proteins were
confirmed by western blotting with anti-HA antibody. (C) Xenograft assay: there was minimal tumor growth after 14 and 28 days in mice
receiving LPP3-deficient SW480 cells (2 × 10
4 tumor cells/site) that expressed vector alone, hLPP1, or hLPP2 constructs. In contrast, tumor
volume was significantly increased in mice receiving SW480 cells that expressed hLPP3 or mLpp3 (n = 12, ¥ P < 0.01 vs. hLPP1 group; n = 12, ¶
P < 0.005 vs. hLPP1 group) at 14 and 28 days.
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PI. Importantly, the tumor volume in mice receiving
hLPP3-RAD + PI was similar to that in mice receiving
vector alone. Representative images of this experiment
are shown in Figure 7D.
Discussion
In this report we showed that LPP3 was constitutively
expressed in a subset of primary tumors and in U87 and
U118 cells, whereas it was undetectable in a human ade-
nocarcinoma E-cadherin deficient SW480 cell line.
Because Wnt/b-catenin signaling is often constitutively
active in many neoplastic cells, we posited that constitu-
tive expression of LPP3 in glioblastoma cells may serve
as a link in the acquisition of proliferative, invasive, and
metastatic phenotypes. Glioblastoma is an aggressive
type of brain tumor [21]. The lethal behavior of glioblas-
toma is characterized by its ability to invade quickly,
usually throughout the normal brain parenchyma, and
to evade apoptosis, thereby rendering it incurable with
traditional chemotherapy and radiation [21,22]. In this
regard, neural stem cells have been shown to differenti-
ate into endothelial cells. In fact, glioblastoma cells
might have the ability to transition into endothelial-like
cells [23-25]. Although LPP3 function is restricted to
endothelial cells, LPP3 could have neural function as
well. Thus, herein we addressed the relationship
between increased LPP3 expression and glioblastoma
tumor growth in vitro and in vivo.
Increased proliferation and migration are key hall-
marks of tumor cells. Beyond binding to VE- or E-cad-
herin, b-catenin transduces Wnt signaling to serve as a
transcriptional co-activator that alters the expression of
target genes involved in cell proliferation, survival, and
differentiation. CYCLIN-D1 is one of the key targets of
the Wnt/b-catenin/LEF-1 transcriptional machinery that
induces the progression of cells through the G1 phase
of the cell cycle. b-catenin and CYCLIN-D1 are major
Figure 7 Domains involved in the regulation of SW480 tumor growth. (A) Schematics of pLNCX2-based retroviral constructs (a-e). Empty
red and blue circles indicate the relative positions of lipid phosphatase and RGD cell adhesion domains, respectively. Filled red and blue circles
indicate phosphatase-inactive (PI) and RAD (adhesion defective) domains, respectively. Black boxes represent transmembrane segments. Three
copies of hemagglutinin (HA) epitopes were fused to the N-terminal and in-frame to the open reading frame of the cDNAs. (B) Equivalent
protein expression and phosphorylation states of b-catenin and CYCLIN-D1 proteins were analyzed by immunoblotting with anti-HA, anti-b-
catenin, anti-p-b-catenin, and anti-CYCLIN-D1 antibodies. Equal loading of proteins across the lanes were determined with the anti-GRB-2
antibody. All blots are representative of those obtained in at least three separate experiments with similar results. (C) LPP3 expression potentiates
SW480 tumor growth. Nude mice were injected subcutaneously with SW480 cells (~ 2 × 10
4) expressing the indicated constructs. After 21 days,
the tumor outgrowths were measured and photographed. (n = 12, ¶ P < 0.005 vs. vector alone group). (D) Representative pictures of primary
tumors in nude mice injected with SW480 cells expressing the indicated constructs.
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LPP3 depletion reduced b-catenin and CYCLIN-D1 pro-
teins, thereby impairing U87 and U118 glioblastoma cell
proliferation and migration. Reduction of b-catenin spe-
cies may have also been due to the increased phosphor-
ylation of b-catenin in these cells. These results strongly
suggest that LPP3 knockdown impedes cell proliferation
and migration by reducing b-catenin and CYCLIN-D1
levels.
Xenograft experiments demonstrate that LPP3 knock-
down decreased the levels of not only b-catenin and
CYCLIN-D1, but also CD133 (a marker of stem-like
cells), VEGF and IL-8. Expression of CD133 by U87 and
U118 cells is consistent with recent reports [23-27];
notably, it has been proposed that CD133+ glioblastoma
tumor cells give rise to tumor endothelium cells [23,24].
Therefore, our results suggest a key role of LPP3 in the
generation of CD133+ cells. VEGF and IL-8 are a pro-
angiogenic growth factor and cytokine, respectively.
Because VEGF and IL-8 are activated by b-catenin sig-
naling [26], it was not surprising that U87 and U118
glioblastoma cells expressed high levels of these two
angiogenic factors [26]. Importantly, LPP3 knockdown
significantly decreased levels of VEGF and IL-8, but not
of TIMP-2, in these cells. Whether LPP3 knockdown
affects differentiation of glioblastoma tumor cells into
tumor endothelium will require detailed investigation.
However, our data suggest that LPP3 knockdown also
affects the level of CD133 protein and secretion of fac-
tors that are required for tumor neovascularization.
In the converse experiment, we determined the impact
of elevated LPP3 expression in LPP3-deficient SW480
colon tumor cells and performed a xenograft assay
using athymic nude mice. In this regard, tumorigenic
SW480 cells harbor two mutant alleles of Adenomatous
Polyposis Coli (APC
mut/mut)g e n e ,b u tn o r m a lb-catenin
[20]. Accordingly, we have demonstrated that the forced
expression of hLPP3 and mLpp3 in SW480 cells poten-
tiated tumor growth and metastasis in the xenograft
assay, whereas hLPP1 and hLPP2 had no effect. Impor-
tantly, the forced expression of LPP3 decreased the
basal phosphorylation status of b-catenin, thereby
enhancing the stability of b-catenin species. Altogether,
these data suggest that the increased proliferation and
tumor growth are LPP3-specific and mediated by
increased b-catenin and CYCLIN-D1 functional activity.
To define the minimal functional domains of LPP3
involved in the potentiation of tumor growth, we gener-
ated retroviral constructs carrying functional mutations.
Stable clones of SW480 cells expressing these constructs
were implanted in nude mice. hLPP3 induced robust
tumor growth, whereas hLPP3-RAD or the hLPP3-PI
supported SW480 tumor growth at a diminished rate.
However, the tumor volume was significantly reduced
(as in control cells) in mice receiving SW480 cells
expressing the hLPP3-RAD + PI construct. These data
suggest that the LPP3 protein has at least two functional
domains, the lipid phosphatase and the LPP3-RGD cell
adhesion domains. The forced expression of LPP3 in
NIH-3T3 fibroblast cells did not transform these cells
(data not shown), suggesting that the LPP3 is not
tumorigenic, but in combination with genetic instability
such as the mutation of APC, elevated expression of
LPP3 potentiates tumor progression by stimulating b-
catenin and CYCLIN-D1 transcriptional activity.
Conclusions
One long-held view is that LPP3 down-regulates cell sig-
naling by virtue of its ability to dephosphorylate S1P and
its structural homologs. In contrast, our data show the
ability of LPP3 to potentiate tumor growth by amplify-
ing b-catenin and CYCLIN-D1 activities. Therefore,
these unexpected set of results implicate LPP3 as a
potential target for inhibiting the growth of glioblastoma
and perhaps other tumors that express high levels of
LPP3.
Methods
Cells and Reagents
Human glioblastoma U87 and U118 cell lines were pur-
chased from the American Type Culture Collection
(Manassas, VA). E-cadherin-deficient (ECD) human
colon adenocarcinoma SW480 (APC
mut/mut) cells were a
kind gift of Dr. Cara Gottardi (Northwestern University,
Chicago, IL). Preparation of rabbit anti-LPP3 polyclonal
antibodies (pAbs) has been described previously [14,15].
Mouse anti-VCIP/LPP3 (39-1000) monoclonal (mAb)
and anti-LPP2 pAb were purchased from Invitrogen
(Carlsbad, CA) and Exalpha Biologicals, Inc (Shirley,
MA), respectively. Anti-CYCLIN-D1 (2978), rabbit anti-
phospho-b-catenin (Ser33, Ser37, and Thr41) and rabbit
anti-CD133 polyclonal antibodies were purchased from
Cell Signaling Technology, Inc. (Denver, MA). Anti-b-
catenin (SC-7963), anti-GAPDH (SC-51906) and anti-
GRB2 pAbs were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Secondary antibodies were
purchased from Promega (Madison, WI).
Immunohistochemistry
Glioblastoma tissue arrays were purchased from U.S.
Biomax Inc. (Rockville, MD). Paraffin-embedded tissues
were collected from normal pancreas and 63 pancreatic
endocrine tumor (PET) affected patients resected at the
University Hospital of Veron a ,I t a l y .I n f o r m e dc o n s e n t
for the analysis of normal and neoplastic tissues was
obtained from patients in accordance with the approval
o ft h eV e r o n aU n i v e r s i t ya n dH o s p i t a lT r u s t ’sE t h i c a l
Committee. Four-micrometer-thick sections were
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Page 9 of 11prepared. Antigen retrieval was performed in 10 mM
citrate buffer (pH 6.0) and heated in a microwave at 360
W for 20 min. Endogenous peroxidase and non-specific
sites were blocked by incubation, respectively, with 3%
H2O2 and 10% goat serum at room temperature. Sec-
tions were then incubated with a rabbit IgG or a rabbit
anti-LPP3-RGD antibody (5 μg / m l )f o r1ha n d3 0m i n
at room temperature, washed three times with PBST
(PBS/0.2% Tween-20), and incubated for 30 min with
anti-rabbit conjugated peroxidase (DakoEnVision+
®,
Peroxidase, Mouse and Rabbit Ready-to-use). After 3
washes with PBST, diaminobenzidine (DAB) (Vector
Biolaboratories, SK-4100) was used as a peroxidase sub-
strate for 10 minutes at room temperature.
Recombinant cDNA constructs, cell culture, retroviral
transduction, and stable cell line generation
pLNCX2 and the amphotropic packaging cell line,
HEK293 (human kidney fibroblasts), were purchased
from BD Biosciences (San Jose, CA). Generation of
recombinant cDNA constructs in pLNCX2 retroviruses
have been described previously [14,15,18]. Control and
LPP shRNA retroviral constructs were purchased from
Origene (Rockville, MD). All transfection experiments
have been previously described [14,15,18]. Stable clones
were selected by western blotting, and LPP expression
levels were determined by immunoblotting as described
previously [14,15,18].
Cell extraction and immunoprecipitation
Cell extracts were prepared using 20 mM Tris (pH 7.5),
150 mM NaCl, 1% Triton X-100, 0.25% NP-40, and 1
mM EDTA buffer. All biochemical experiments, includ-
ing western blot (WB) analyses, were performed as
described previously [14,15,18,28]
Cell migration assay
Migration assay was carried out as described previously
[18]. In brief, modified transwell Boyden chambers (8
μM) were used for chemotactic cell migration. Human
U87 and U118 cell were plated overnight in complete
media, next day cells at 60% density were infected with
control- or LPP3-shRNA retroviral particles for 12
hours. Media containing viral particles were removed
and replenished with media with containing insulin,
transferrin and selenium (hereafter called Migration
Assay Media, MAM) without serum. After 4 hours, cells
detached with 2 mM EDTA, pH 7.4, pelleted, washed
twice with PBS (pH 7.5), and resuspended in MAM.
The upper chamber was filled with 400 μl of MAM con-
taining ~1 × 10
4 cells, and the lower chamber was filled
with 500 μl of MAM, no chemo-attractant was used.
Cells were incubated for 6 h at 37°C in a CO2 incuba-
tor. After 6 hours, inserts were retrieved and cells in the
upper chamber removed with q-tips, while cells
migrated to the lower face of the membrane were fixed
and stained with 0.5% crystal violet. Excess dye was
washed with running tap water, membranes were then
examined using a phase-contrast microscope. At least
seven 200 × magnification fields were selected for scor-
ing. Cell migration assay was repeated 3 times with each
trial being performed in triplicate.
Enzyme-linked Immunosorbent Assay (ELISA)
ELISAs were performed as described previously [18,28].
To monitor the secretion of VEGF, IL-8, and TIMP-2,
U87 and U118 cell lines were left in medium containing
5 μg/ml puromycin for 24 hours. Then, the cell culture
media was collected, centrifuged and subjected to ELISA
according to the manufacturer’sr e c o m m e n d a t i o n s
(Research Diagnostics and R & D Systems). The ELISA
detection limit for each factor ranged from 6 pg/ml to
1600 pg/ml, and the intra- and inter-assay variations
were 4.1-6.2% and 6.5-10%, respectively.
Xenograft assay
All experiments described in this study were carried out
according to the University of Illinois (UIC) Animal
Care Committee (ACC) and NIH guidelines. Eight-week
old female (~25 g) athymic nude mice from Jackson
Laboratory (Bar Harbor, ME) were used for this study.
SW480 cells expressing vector (pLNCX2) alone and var-
ious LPP constructs were trypsinized, resuspended and
washed with sterile PBS, pH 7.4. After resuspension in
PBS, pH 7.4, cells were passed through a 100 μMc e l l
strainer and enumerated using a hemocytometer. Cells
(2 × 10
4 in 150 μl) were subcutaneously (s.c.) injected
into each of 12 animals (n = 12) per group. Tumor
growth was monitored for 21 or 28 days. One mouse
from each group was selected randomly, anesthetized,
photographed, and sacrificed and the tissues were recov-
ered for further analysis.
Statistics
Analysis of variance (ANOVA) was used for statistical
analyses and values of P < 0.05 were considered statisti-
cally significant. Data represent means ± s.e.m. All ana-
lyses were performed using GraphPad Prizm 5.0
software (La Jolla, CA).
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